Clinical Trials

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT07209449 2026-03-18

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Phase 1/2 Not yet recruiting

75 enrolled

Gynecologic

Recurrence, Endometrial Neoplasms

NCT07416188 2026-03-18

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

40 enrolled

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT07480213 2026-03-18

DART-NK-SCLC

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT07480954 2026-03-18

DUAL-OV-CAR-NK

Phase 3 Active not recruiting

36 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT05552976 2026-03-17

SUCCESSOR-2

525 enrolled

Multiple Myeloma, Recurrence

NCT06161519 2026-03-17

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

146 enrolled

Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Recurrence

NCT06189391 2026-03-17

MK-1045-001

100 enrolled

Recurrence, Lymphoma, B-Cell

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT07156565 2026-03-17

ATLAS

Sarcoma

Recurrence, Sarcoma

NCT07164560 2026-03-17

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

45 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07221253 2026-03-17

AB02

Phase NA Not yet recruiting

1,100 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT07478705 2026-03-17

EINSTEIN-TNBC

Phase 1 Active not recruiting

Recurrence, Triple Negative Breast Neoplasms

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

28 enrolled

Other hematologic neoplasm

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT04347616 2026-03-16

NK4AML

Phase 1/2 Terminated

9 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

160 enrolled

Other hematologic neoplasm

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04926285 2026-03-16

VEN-OM

Phase 1 Completed

6 enrolled

Recurrence, Hematologic Neoplasms

NCT07137494 2026-03-16

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

12 enrolled

Lymphoma, Recurrence

NCT07297979 2026-03-16

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

50 enrolled

Sarcoma

Recurrence, Sarcoma, Ewing

NCT03460977 2026-03-13

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

453 enrolled

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT05588141 2026-03-13

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

96 enrolled

Brain Neoplasms, Glioma, Neoplasms, Recurrence

NCT05652335 2026-03-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

180 enrolled

Phase 1 Active not recruiting

Amyloidosis, Multiple Myeloma, Recurrence

NCT06425991 2026-03-13

MajesTEC-10

108 enrolled

Multiple Myeloma, Recurrence

NCT06604715 2026-03-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

80 enrolled

Multiple Myeloma, Recurrence

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

Multiple Myeloma, Recurrence

NCT05519085 2026-03-11

SUCCESSOR-1

810 enrolled

Multiple Myeloma, Recurrence

NCT03458260 2026-03-10

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Phase 2 Completed

74 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT05748197 2026-03-10

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

Other hematologic neoplasm

40 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

68 enrolled

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT07257419 2026-03-10

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recurrence, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

43 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT05669846 2026-03-09

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06704659 2026-03-09

RAY-no-BAN

Phase NA Recruiting

Phase 2 Not yet recruiting

Breast Neoplasms, Recurrence

NCT07458204 2026-03-09

EPPIL

760 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT03361306 2026-03-06

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

15 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

281 enrolled

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05533775 2026-03-06

iMATRIX GLO

65 enrolled

Recurrence

NCT06149286 2026-03-06

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06375044 2026-03-06

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

130 enrolled

Phase 1 Enrolling by invitation

Multiple Myeloma, Recurrence

NCT06508138 2026-03-06

J21112LINKED

24 enrolled

Neoplasm Metastasis, Recurrence

NCT05927571 2026-03-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

120 enrolled

Multiple Myeloma, Recurrence

NCT07280013 2026-03-05

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Phase 2 Not yet recruiting

Bites and Stings, Multiple Myeloma, Recurrence

NCT07453095 2026-03-05

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

41 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT03601078 2026-03-04

KarMMa-2

Phase 2 Completed

312 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT04416984 2026-03-04

ALPHA2

160 enrolled

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06321484 2026-03-04

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer